Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of VMP versus high-dose melphalan/ASCT with VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma
NL-OMON28960Phase 3Not yet recruiting
- Sponsor
- HOVON
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, melphalan, prednisone, lenalidomide, dexamethasone and 1 more in multiple myeloma (MM) (5 arms), sponsored by HOVON. Primary endpoints: Progression-free survival from registration, Progression-free survival from randomization 1 and 1 more. Planned start Oct 2010; status: not yet recruiting.
02
Drugs
bortezomibmelphalanprednisonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON28960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28960.